Investigative Ophthalmology & Visual Science Cover Image for Volume 61, Issue 7
June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Ocular Surface disease indicators in make-up wearers
Author Affiliations & Notes
  • Clare Halleran
    East Coast Eye Care, Clarenville, Newfoundland, Canada
  • Leslie O'Dell
    DE Center of Pennsylvannia, Pennsylvania, United States
  • Tracy Doll
    Pacific University, Oregon, United States
  • Scott Schwartz
    Private Practice, Michigan, United States
  • Milton M Hom
    Private Practice, California, United States
  • Footnotes
    Commercial Relationships   Clare Halleran, Allergan (C), Shire Canada (C); Leslie O'Dell, Aerie (C), Alcon (C), Allergan (C), Bausch Health (C), EyeEco (C), JNJVision (C), Novartis (S), SightSciences (C), Sun (C); Tracy Doll, Allergan (C), Bauch and Lomb (C), Novartis (C), Sun (C), Tissue Tech (C); Scott Schwartz, Alcon (F), Bausch Health (F); Milton Hom, Allergan (C), Bausch Health (C), EyeNovia (C), Eyevance (C), Hovione (C), Kala Pharmaceuticals (C), Novartis (C), Tarsus (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 328. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Clare Halleran, Leslie O'Dell, Tracy Doll, Scott Schwartz, Milton M Hom; Ocular Surface disease indicators in make-up wearers. Invest. Ophthalmol. Vis. Sci. 2020;61(7):328.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Make-up wear is a fairly tumultuous topic when it comes to its impact on ocular health. Past study in this area suggested that make-up wearers may be more symptomatic for dry eye as well as exhibit morphological Meibomian gland change. This study was developed to advance the knowledge base and to help evaluate whether make-up wearers exhibit symptoms of dry eye as well as further examine Meibomian gland morphology and function in make-up wearers.

Methods : This multi-clinic study looked at the results of questionnaires asking female patients to detail make up habits and self-evaluate their dry eye symptoms using validated questionnaires (OSDI, UNC and SPEED). All study participants also underwent infrared meibography of their upper and lower lids with various meibography imaging equipment (Lipiview 2, Oculus Keratograph 5M & Lipiscan). Clinicians were asked to grade Meibomian gland expression on a scale of 0-4 and Pult’s scale for gland atrophy was used to grade atrophied glands. A paired TTest was used to analyze the data set.

Results : Data was compiled from 5 different clinic sites. No males reported wearing make-up thus they were eliminated from the study. A total of 100 female eyes were tested (n=50) with the average age of Make-up (MU) users 55.8 and the average age of non-make-up users (NMU) 49.7. MU patients did report more dry eye symptoms on all dry eye symptom surveys than that of NMU patients. UNC mean was 3.85 (SD= 1.8) for MU mean of 2.5 (SD=2.2) in NMU, Mean SPEED scores for MU was 9.5 (SD=4.2) and NMU 5.6 (SD=6.3), OSDI mean was 23 in MU (SD= 13) and 10.2 in NMU (SD=13). All scores were statistically different between the 2 groups (p-values: UNC =0.017, OSDI=0.0014, SPEED=0.019). There was no significant difference in gland drop-out between the two patient groups however there was a significant difference in meibomian gland expression (p<0.001)

Conclusions : Make-up use is very common amongst patients in regular clinical practice. This study showed the importance of evaluating patients who report use of make-up for dry eye symptoms as well as Meibomian gland function. Use of make-up may be exacerbating dry eye symptomology and progression of ocular surface disease when it comes to Meibomian gland structure. Further study of particular make-up habits and their effect on Meibomian glands and ocular surface disease progression may help to gain additional insight of risk of disease in this patient population.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×